Story perspectives
Alzheimer's Market Soars Amid FDA Approvals, Lilly Stocks Fall
1/18/2025
23 5
1 of 1
Story summary
- The Alzheimer’s market is projected to expand from $2.4 billion in 2023 to $19.3 billion by 2033, fueled by new therapies like Leqembi and Kisunla.
- Eli Lilly's stock dropped nearly 7% after revising its fourth-quarter sales forecast to $13.5 billion, below expectations.
- Lilly's Alzheimer’s drug Kisunla received FDA approval, demonstrating potential in slowing cognitive decline.
